Trials / Completed
CompletedNCT04740814
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab pegol | * Pharmaceutical form: Solution for injection * Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study. |
Timeline
- Start date
- 2021-02-11
- Primary completion
- 2022-01-24
- Completion
- 2022-06-27
- First posted
- 2021-02-05
- Last updated
- 2024-02-12
- Results posted
- 2023-11-13
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04740814. Inclusion in this directory is not an endorsement.